IL-4/IL-13 and IL-13 for moderate to severe AD

CE / CME

Advanced Biologic Therapies Targeting IL-4/IL-13 and IL-13 Axis in Moderate to Severe Atopic Dermatitis

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: May 16, 2025

Expiration: May 15, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Jeremy, a 39-year-old man with refractory moderate to severe atopic dermatitis (AD), visits his doctor’s office for intense itching and widespread lesions. He has been struggling with AD since his childhood. He reports poor quality of life despite using topical corticosteroids and systemic corticosteroids for severe flares. His dermatologist is considering initiating a biologic therapy targeting interleukin (IL)-13.

Based on Jeremy’s clinical presentation and the mechanism of IL-13 in AD, what is the primary therapeutic benefit of choosing an IL-13–targeting biologic for his treatment?